Histogenics (HSGX) Misses Q3 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. AMD
3. PLTR
4. CRWD
5. DOX
6. VRTX
7. CHKP
8. ON
9. HNGE
10. INSP

Go back to Histogenics (HSGX) Misses Q3 EPS by 9c

Histogenics Corporation Announces Third Quarter 2015 Financial and Operating Results

November 12, 2015 6:30 AM EST

- Completion of Enrollment of NeoCart® Phase 3 Trial Now Expected in Second Quarter of 2017 -

- Company to Host Conference Call and Webcast Today at 8:30 a.m. EST -

WALTHAM, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the quarter ended September 30, 2015.

With our new team fully in-place, we are working aggressively to enroll our NeoCart Phase 3 clinical trial, complete the... More